Filtered By:
Condition: Ischemic Stroke
Drug: Plavix

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 1287 results found since Jan 2013.

rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome
Conclusions Behavioral outcomes are improved with females with higher endogenous estrogen levels treated with standard dose antiplatelet loading. This is the first non-rodent study to demonstrate that higher endogenous estrogen levels in female rabbits appear to be neuroprotective in ischemic stroke. This research supports the further study of the effect of endogenous estrogen levels on outcome with standard dose antiplatelet loading in stroke patients not eligible for revascularization therapies.
Source: Biology of Sex Differences - July 15, 2014 Category: Biology Source Type: research

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk
Conclusion Left atrial appendage closure in patients with non-valvular atrial fibrillation and high risk for stroke and bleeding events effectively prevented stroke and reduced cerebral ischemic events compared to expected stroke rate according to CHA2DS2-VASc Score. Dual antiplatelet therapy for 3 months reduced the rate of bleeding events compared to 6 months therapy with no increase of thrombotic events.
Source: Clinical Research in Cardiology - August 29, 2015 Category: Cardiology Source Type: research

Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
CONCLUSIONS: For the treatment of high-risk TIA or minor stroke patients, the clopidogrel-aspirin treatment did not increase the number of CMB than Aspirin alone. It appears that the extent of CMB was associated with the extent of existing CMB occurred in previous stroke, which was mostly located in cortical, subcortical zone. PMID: 26391570 [PubMed - in process]
Source: Neurological Research - September 25, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Controversies in antiplatelet therapy in the secondary prevention of stroke
Publication date: Available online 19 January 2016 Source:European Geriatric Medicine Author(s): T. Adamek Recurrence of stroke has been estimated at 3–4% yearly after TIA or stroke. There is no clear agreement in choosing antiplatelet therapy at this time. Europeans, Americans and British guidelines have been different. Aspirin is still used in secondary prevention of ischemic stroke, because of the longest experience with the best-achieved results in different studies and low price. Other used drugs are a combination of aspirin and dipyridamole, P2Y12 receptor antagonists – clopidogrel, ticlopidine, prasugrel an...
Source: European Geriatric Medicine - January 20, 2016 Category: Geriatrics Source Type: research

Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons
Abstract Anti-platelet treatments, an effective anti-thrombotic therapy, are widely used in non-cardioembolic ischemic stroke or transient ischemic attack (TIA), including aspirin, cilostazol, clopidogrel, and other mono or dual therapies, while the optimal choice remains uncertain. All the literatures of 38 eligible randomized control trials were searched in PubMed, Embase, and China National Knowledge Internet (CNKI) without language limitation. And, nine anti-platelet therapies were assessed, including aspirin, clopidogrel, cilostazol, ticlopidine, triflusal, terutroban, sarpogrelate, dipyridamole plus aspirin,...
Source: Molecular Neurobiology - February 5, 2016 Category: Neurology Source Type: research

Clopidogrel and Smoking Status Among Ischemic Stroke Patients: Smokers Paradox? (P1.122)
Conclusions: We found that ischemic stroke patients who actively smoked derived a slight yet non statistically significant benefit from clopidogrel compared to aspirin for vascular risk reduction. This issue needs to be further evaluated in additional studies of larger size.Disclosure: Dr. Zhang has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Song has nothing to disclose. Dr. Ji has nothing to disclose. Dr. Hou has nothing to disclose. Dr. Cao has nothing to disclose. Dr. Dong has nothing to disclose. Dr. Huang has nothing to disclose. Dr. Feng has nothing to disclose. Dr. Ovbiagele has nothing to disclose. ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Zhang, Q., Wang, Y., Song, H., Ji, X., Hou, C., Cao, Q., Dong, K., Huang, X., Feng, W., Ovbiagele, B., Wang, M. Tags: Cerebrovascular Disease: Epidemiology Source Type: research

Pharmacogenetics of CYP2C19 Genetic Polymorphism on Clopidogrel Response in Patients with Ischemic Stroke from Saudi Arabia (P5.213)
Conclusion: Our findings provide certain evidence on genetic effect of CYP2C19 on clopidogrel responsiveness in stroke patients from SaudiDisclosure: Dr. Alhazzani has nothing to disclose. Dr. Munisamy has nothing to disclose. Dr. Karunakaran has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alhazzani, A. A., Munisamy, M., Karunakaran, G. Tags: Cerebrovascular Disease: Genetics and Risk Factor Variation Source Type: research

Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population
Abstract To evaluate the prevalence and risk factors of antiplatelet drug resistance and its association with early neurological deterioration (END) and recurrent ischemic stroke (RIS) in patients with acute minor stroke. Antiplatelet drug resistance was assessed by platelet aggregation assay in 426 patients with minor stroke who were receiving combined treatment of aspirin and clopidogrel. All patients were followed up for 90 days. The primary endpoint of the study was END within 10 days after admission. The secondary endpoints included RIS, myocardial infarction and death during 90 days of treatment. The safe...
Source: Journal of Neurology - June 2, 2016 Category: Neurology Source Type: research

The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Abstract PURPOSE: The goal of this study was to compare the relative efficacy and safety of different types of interventions for stroke prevention in patients with cardiovascular and cerebrovascular diseases. METHODS: This network meta-analysis (NMA) was conducted with a random effects model of Bayesian framework using Stata version 12.0. Odds ratios (ORs) and their credible intervals (CrIs) were applied for the efficacy and safety evaluation of various medical interventions, including aspirin, dipyridamole, ticlopidine, warfarin, and apixaban. In addition, the ranking of probability of every clinical outcome...
Source: Clinical Therapeutics - June 10, 2017 Category: Drugs & Pharmacology Authors: Sun Q, Chang S, Lu S, Zhang Y, Chang Y Tags: Clin Ther Source Type: research

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.
In conclusion, we have demonstrated the clinical impact of CYP2C19*2 on clopidogrel efficacy using a purely EMR approach. This suggests that the risk in the ischemic stroke population may be particularly high. This article is protected by copyright. All rights reserved. PMID: 28653333 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - June 27, 2017 Category: Drugs & Pharmacology Authors: Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF Tags: Clin Pharmacol Ther Source Type: research

Letter re: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE
We read with interest the article by Pan et al.,1 which reported that the use of dual antiplatelet therapy (DAPT) showed an early benefit, compared to aspirin alone, for secondary ischemic stroke prevention after a minor stroke or TIA. The absolute risk reduction in the first week after the indexed event was 4.5%.1 The authors previously reported a nonsignificant absolute risk reduction in recurrent ischemic stroke of 2.3% with DAPT compared to aspirin alone in Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) participants with intracranial arterial stenosis (ICAS) over the 90-day fo...
Source: Neurology - November 13, 2017 Category: Neurology Authors: Gutierrez, J., Lekic, T. Tags: WRITECLICK & amp;reg; EDITOR ' S CHOICE Source Type: research

A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.
CONCLUSIONS: This article presents the study design and rationale for a trial investigating the noninferiority of prasugrel to clopidogrel sulfate with regards to the inhibitory effect on primary events in patients with non-cardioembolic stroke. PMID: 29463150 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - February 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Conclusions: Among IS patients treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had a significantly higher rate of adverse vascular events than did noncarriers. It should avoid prescribing clopidogrel to these patients with known CYP2C19 polymorphisms. PMID: 29707143 [PubMed]
Source: Oncotarget - May 2, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
Conclusions: The results will bring about vigorous evidence in this issue and guide both clinical decision-making and future research.
Source: Medicine - June 1, 2018 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: A pilot study
Conclusion: Unlike aspirin, a high proportion of nonresponders to clopidogrel was identified. In an interim analysis on 65 Indian patients, a significant association was found between CYP2C19*2 and clopidogrel nonresponsiveness.
Source: Annals of Indian Academy of Neurology - April 8, 2019 Category: Neurology Authors: Samir Patel Vandana Arya Amrita Saraf Manorama Bhargava CS Agrawal Source Type: research